ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area
examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is
rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it
is critical to preserve the effective life of SP by using it in combination with artesunate.
Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for
treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.
Phase:
Phase 3
Details
Lead Sponsor:
Gates Malaria Partnership London School of Hygiene and Tropical Medicine
Collaborators:
HealthNet TPO Malaria Control Program, Directorate of Malaria Control, Pakistan Pakistan Directorate of Malaria Control United Nations High Commissioner for Refugees World Health Organization